<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8393">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02119104</url>
  </required_header>
  <id_info>
    <org_study_id>B1851122</org_study_id>
    <nct_id>NCT02119104</nct_id>
  </id_info>
  <brief_title>Prevenar (13v) Infant Drug Use Investigation</brief_title>
  <official_title>Prevenar (13v) Infant Drug Use Investigation (Regulatory Post Marketing Commitment Plan) - Investigation in Infants Starting Vaccination at the Age of 2 Months, Inclusive, to 7 Months, Exclusive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate post marketing use and safety of Prevnar ( 13v)
      in infants vaccinated for the first time at the age of 2 months, inclusive, to 7 months,
      exclusive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigation will be conducted using the continuous investigation method, with which a
      satisfying registration conditions will be continuously registered until the number of
      contracted cases is reached.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of the participants with adverse reaction</measure>
    <time_frame>52 weeks (MAX)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Infants</condition>
  <arm_group>
    <arm_group_label>Prevenar (13v)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevenar (13v)</intervention_name>
    <description>Prevenar (13v)</description>
    <arm_group_label>Prevenar (13v)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Vaccinees who meet all of the following conditions at the time of the first vaccination
        among infants who use Prevenar 13 in accordance with the indication, and dosage and
        administration of the vaccine will be included in the investigation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vaccinees who meet all of the following conditions at the time of the first
             vaccination among infants who use Prevenar 13 in accordance with the indication, and
             dosage and administration of the vaccine will be included in the investigation:

          -  Infants aged 2 months, inclusive, to 7 months, exclusive

          -  Infants with no history of administration of pneumococcal vaccines including Prevenar
             13

          -  Infants expected to receive 4 vaccinations

        Exclusion Criteria:

          -  Vaccines must not be performed if the vaccinee corresponds to any of the following:

          -  Persons in whom a past history of anaphylaxis due to an ingredient of Prevenar 13 or
             diphtheria toxoid is evident

          -  Persons with evident pyrexia

          -  Persons who evidently have serious acute diseases

          -  Besides the persons listed above, persons who are in a status inappropriate for
             immunization
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>7 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851122&amp;StudyName=Prevenar%20%2813v%29%20Infant%20Drug%20Use%20Investigation</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
